Azithromycin in upper respiratory tract infections: a clinical trial in children with otitis media.
Azithromycin is a newly developed azalide antibiotic which is very active against microbes causing respiratory tract infections; tissue concentrations remain elevated for a long time after discontinuation of treatment. A clinical study was conducted to compare azithromycin (10 mg/kg administered as a single daily dose for 3 days) with amoxycillin/clavulanic acid (50 mg/kg/day given b.i.d. for 10 days) in 30 children with otitis media. Sensitivity testing demonstrated good azithromycin activity against beta-haemolytic streptococci, Moraxella catarrhalis, Haemophilus influenzae and Staphylococcus aureus. By day 12, clinical cure was recorded in 14/15 children treated with azithromycin and this was maintained at day 30. In the day 12 and 13/15 children by day 30. It was concluded that a 3-day azithromycin regimen produces a satisfactory clinical response and the eradication of key pathogens, and was acceptable for children.
Pestalozza
G
G
Department of Otolaryngology, Ospedale dei Bambini V. Buzzi, Milan, Italy.
Cioce
C
C
Facchini
M
M
D000284:Administration, Oral; D000658:Amoxicillin / Q000627:therapeutic use; D017963:Azithromycin; D002648:Child; D002675:Child, Preschool; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D010033:Otitis Media / Q000188:drug therapy* / Q000382:microbiology; D010034:Otitis Media with Effusion / Q000188:drug therapy* / Q000382:microbiology
D002969:Clavulanic Acids; D019818:Clavulanic Acid; D004917:Erythromycin; D000658:Amoxicillin; D017963:Azithromycin